Department of Pharmacy, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore.
Division of Supportive and Palliative Care, National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610, Singapore.
Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):29-36. doi: 10.1007/s10096-021-04325-z. Epub 2021 Aug 20.
Antimicrobial therapy in terminally ill patients remains controversial as goals of care tend to be focused on optimizing comfort. International guidelines recommend for antibiotic stewardship program (ASP) involvement in antibiotic decisions in palliative patients. The primary objective was to evaluate the clinical impact of ASP interventions made to stop broad-spectrum intravenous antibiotics in terminally ill patients. This was a retrospective chart review of 459 terminally ill patients in Singapore General Hospital audited by ASP between December 2010 and December 2018. Antibiotic duration, time-to-terminal discharge for end-of-life care, time-to-mortality, and mortality rates of patients with antibiotics ceased or continued upon ASP recommendations were compared. A total of 283 and 176 antibiotic courses were ceased and continued post-intervention, respectively. The intervention acceptance rate was 61.7%. The 7-day mortality rate (47.3% vs 61.9%, p = 0.003) was lower in the ceased group, while 30-day mortality rate (76.0% vs 81.2%, p = 0.203) and time-to-mortality post-intervention (3 [0-24] vs 2 [0-27] days, p = 0.066) did not differ between the ceased and continued groups. After excluding the 57 patients who had antibiotics continued until death within 48 h of intervention, only time-to-mortality post-intervention was statistically significantly shorter in the ceased group (3 [0-24] vs 4 [0-27], p < 0.001). Of the 131 terminally discharged patients, antibiotic duration (4 [0-17] vs 6.5 [1-14] days, p = 0.001) and time-to-terminal discharge post-intervention (6 [0-74] vs 10.5 [3-63] days, p = 0.001) were shorter in the ceased group. Antibiotic cessation in terminally ill patients was safe, and was associated with a significantly shorter time-to-terminal discharge.
终末期患者的抗菌治疗仍然存在争议,因为治疗目标往往侧重于优化舒适度。国际指南建议在姑息治疗患者的抗生素决策中纳入抗生素管理计划(ASP)。主要目的是评估 ASP 干预措施停止终末期患者广谱静脉抗生素的临床影响。这是对 2010 年 12 月至 2018 年 12 月期间新加坡综合医院 ASP 审核的 459 名终末期患者进行的回顾性图表审查。比较了根据 ASP 建议停止或继续使用抗生素的患者的抗生素持续时间、临终关怀的终末出院时间、死亡时间和死亡率。分别有 283 例和 176 例抗生素疗程在干预后停止和继续。干预接受率为 61.7%。停止组的 7 天死亡率(47.3%比 61.9%,p=0.003)较低,而 30 天死亡率(76.0%比 81.2%,p=0.203)和干预后死亡时间(3 [0-24]比 2 [0-27]天,p=0.066)在停止和继续组之间没有差异。排除干预后 48 小时内抗生素持续至死亡的 57 例患者后,仅停止组的干预后死亡时间明显缩短(3 [0-24]比 4 [0-27],p<0.001)。在 131 名终末期出院的患者中,停止组的抗生素持续时间(4 [0-17]比 6.5 [1-14]天,p=0.001)和干预后终末出院时间(6 [0-74]比 10.5 [3-63]天,p=0.001)较短。终末期患者停止使用抗生素是安全的,与终末出院时间明显缩短有关。